Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282251 | 0.90 | MEN1 (0.60) | NOTUMMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL16233330 | 0.88 | NOTUM (0.48) | NOTUMMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL11912017 | 0.87 | NOTUM (0.47) | NOTUMMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL1091007 | 0.83 | PKM (0.49) | NOTUMMEN1KMT2AMAPTNPC1 | |
| SCHEMBL1091028 | 0.83 | MEN1 (0.46) | NOTUMMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL10165495 | 0.83 | POLB (0.47) | NOTUMMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10165483 | 0.83 | POLB (0.49) | NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL1091717 | 0.80 | MAPT (0.45) | NOTUMMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL1091092 | 0.79 | KDM4E (0.49) | L3MBTL1SMN1; SMN2GSK3AGSK3BDYRK3 | |
| SCHEMBL16234628 | 0.79 | GSK3A (0.45) | NOTUMGSK3AGSK3BDYRK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| EP-1673357-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCNN1G, KCNN3, KCNN2 | NOTUM 2056/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | NOTUM 2056/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | NOTUM 2056/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | NOTUM 2056/4885MEN1 2329/4885KMT2A 3111/4885 |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | NOTUM 2056/4885MEN1 2329/4885KMT2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.